Cellectis S.A. (CLLS) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Cellectis S.A. (CLLS) over the past year, losing 19.3% versus a loss of 70.9%. Over five years, CLLS leads with a -88.5% price change compared with -97.2% for NRXP. Cellectis S.A. is the larger company by market cap ($125.9 million vs $125.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | NRXP |
|---|---|---|
| Share price | $1.25 | $2.89 |
| Market cap | $125.90M | $125.12M |
| 1-day change | -6.72% | -0.34% |
| YTD return | -74.17% | +6.64% |
| 1-year return | -70.93% | -19.27% |
| 5-year return | -88.46% | -97.18% |
| EPS (TTM) | $-0.64 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $5.06 |
| 52-week low | $1.22 | $1.62 |
| Distance from 52-week high | -77.19% | -42.83% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +326.40% | +1232.18% |
| Average volume | 80.14K | 865.49K |
| Shares outstanding | 72.72M | 43.30M |
| Employees | 224 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed CLLS by 51.7 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
CLLS vs NRXP FAQ
Which is bigger, Cellectis S.A. or NRX Pharmaceuticals?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $125.90M compared with $125.12M for NRX Pharmaceuticals (NRXP).
Which stock has performed better over the past year, CLLS or NRXP?
NRXP returned -19.27% over the past 12 months, compared with -70.93% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.